A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

September 21, 2028

Study Completion Date

September 21, 2028

Conditions
Malignant Peritoneal MesotheliomaPeritoneal MesotheliomaMesotheliomaMesothelioma, MalignantMalignant Mesothelioma
Interventions
DRUG

Pemetrexed

Pemetrexed will be administered intravenously

DRUG

Cisplatin

Cisplatin will be administered intravenously

DRUG

Carboplatin

Possible substitution with carboplatin based on clinician discretion

Trial Locations (13)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activites), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

15212

RECRUITING

Allegheny Health Network (Data Collection Only), Pittsburgh

48109

NOT_YET_RECRUITING

University of Michigan (Data Collection Only), Ann Arbor

60637

RECRUITING

University of Chicago (Data Collection Only), Chicago

63110

NOT_YET_RECRUITING

Washington University (Data Collection Only), St Louis

68198-7680

NOT_YET_RECRUITING

University of Nebraska (Data collection only), Omaha

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

08903

NOT_YET_RECRUITING

Rutgers University (Data Collection Only), New Brunswick

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER